BUZZ-Immunome drops on stock offering

Shares of Immunome Inc IMNM.O down 10.2% to $8.40 post-market as biotech firm looks to raise equity

Bothell, Washington-based oncology specialist commences $125 mln stock offering

Co intends to use net proceeds to fund clinical and preclinical development of pipeline assets, and general purposes, per the SEC filing

JP Morgan, TD Cowen, Leerink and Guggenheim are jt bookrunners

With ~62.4 mln shares outstanding, IMNM has ~$583 mln market cap, per LSEG data

Shares closed up 1.2% at $9.35 on Weds. Still, stock has lost 12% YTD and about 50% over the past 12 months